Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
492 daily bars · split adjusted
Current price $8.34
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Aug 17, 26 |
Daily · Wilder smoothing
| HC Wainwright & Co. |
| maintain |
| Buy |
| Buy |
| May 22, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Apr 27, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Dec 19, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Oct 20, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| May 16, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Apr 1, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Mar 31, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 41.25 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 28.00 | Oscillator | Neutral |
| Williams %R (14) | -74.10 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.13 (Hist -0.05) | Oscillator | Strong Sell |
| Average Directional Index (14) | 16.76 (+DI 11.4 / -DI 22.7) | Trend | Neutral |
| EMA 20 | 8.66 | MA | Strong Sell |
| SMA 20 | 8.73 | MA | Strong Sell |
| EMA 50 | 8.68 | MA | Strong Sell |
| SMA 50 | 8.94 | MA | Strong Sell |
| SMA 200 | 7.08 | MA | Strong Buy |
TTM vs. 5-year historical average (annual ratios)
| Metric | ACOG | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -7.6x | -2.5x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -6.3x | EPS est. -1.32 | Discount |
| Price / Book | 3.4x | -3.1x | Discount |
| Price / Sales | 8.5x | 2.2x | Elevated |
| EV / EBITDA | -3.2x | -1.1x | Elevated |
| Return on equity | -45.3% | — | Weak |
| Gross margin | 89.9% | 16.3% | Above hist. |
| Debt / Equity | 0.00 | -0.21 | Conservative |
| Piotroski / Altman Z | 2/9 | Z 6.59 | Safe zone |
Discounted cash flow model
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 16, 26 | Opaleye Management Inc. | 10 percent owner | P-Purchase | 14,283 @ $8.23 | $117.6K |
| Oct 15, 26 |
| Opaleye Management Inc. |
| 10 percent owner |
| P-Purchase |
| 22,657 @ $8.43 |
| $191.0K |
| Oct 1, 26 | Opaleye Management Inc. | 10 percent owner | P-Purchase | 19,050 @ $8.69 | $165.6K |
| Sep 25, 26 | Opaleye Management Inc. | 10 percent owner | P-Purchase | 13,426 @ $8.47 | $113.7K |
| Sep 24, 26 | Opaleye Management Inc. | 10 percent owner | P-Purchase | 18,337 @ $8.57 | $157.1K |
| Sep 16, 26 | Opaleye Management Inc. | 10 percent owner | P-Purchase | 27,141 @ $8.40 | $228.0K |
| Sep 16, 26 | Opaleye Management Inc. | 10 percent owner | P-Purchase | 53,029 @ $8.57 | $454.6K |
| Sep 15, 26 | Opaleye Management Inc. | 10 percent owner | P-Purchase | 3,375 @ $8.54 | $28.83K |
Stock news · updated daily
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition" or the "Company"), a biopharmaceutical company developing and commercializing novel therapeutics for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) published U.S. Patent Application No. 19/090,242, titled “Process for Preparing Benzgalantamine and Salts Thereof,” on October 1, 2026, as U.S. Patent Applicatio.
Shares of Alpha Cognition Inc. (NASDAQ: ACOG - Get Free Report) have earned a consensus rating of "Buy" from the five brokerages that are covering the stock, Marketbeat reports. Five investment analysts have rated the stock with a buy recommendation. The average 1 year price target among brokers that have issued a report on the stock
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that new clinical and real-world data on ZUNVEYL and acetylcholinesterase inhibitors will be presented at the American Society of Consultant Pharmacists (ASCP) Annual Meeting, taking place October 29-November 1, 2026 and Neuroscience Education I.
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that on October 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 6,000 shares of common stock to a.
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition," "ACI," or the "Company") today announced initial results from CONVERGE, an ongoing retrospective real-world evidence evaluation using longitudinal long-term care medication-administration data. As part of the ongoing CONVERGE evidence-generation program, this analysis focused on 180-day titration and concomitant medication patterns among residents receiving ZUNVEYL (benzgalan.
Karyopharm Therapeutics (NASDAQ: KPTI - Get Free Report) and Alpha Cognition (NASDAQ: ACOG - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations. Analyst Ratings This is a breakdown of
Alpha Cognition Inc. (NASDAQ: ACOG - Get Free Report) has received an average rating of "Buy" from the five analysts that are presently covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have issued ratings on the stock in the last
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that on September 8, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 25,000 shares of common stock to.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | -0.39 | -0.40 | Miss -2.0% | $6.00M |
| May 14, 2026 | -0.41 | -0.37 | Beat 9.8% | $3.53M |
| Mar 26, 2026 | -0.27 | -0.30 | Miss -11.1% | $2.80M |
| Nov 13, 2025 | -0.43 | -0.08 | Beat 81.0% | $2.80M |
| Aug 14, 2025 | -0.46 | -0.65 | Miss -41.3% | $1.66M |
| May 15, 2025 | -0.58 | -0.20 | Beat 65.5% | $2.91M |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 19, 2026 | 2026-10-19 17:34:04 | View |
| 4 | Oct 2, 2026 | 2026-10-02 16:05:22 | View |
| 4 | Sep 28, 2026 | 2026-09-28 19:57:34 | View |
| SC 13G | Sep 23, 2026 | 2026-09-23 18:13:02 | View |
| 4 | Sep 16, 2026 | 2026-09-16 17:57:41 | View |
| 4 | Aug 24, 2026 | 2026-08-24 14:52:45 | View |
| 10-Q | Aug 13, 2026 | 2026-08-13 16:48:02 | View |
| 4 | Aug 4, 2026 | 2026-08-04 16:50:08 | View |
| 4 | Jul 28, 2026 | 2026-07-28 16:05:29 | View |
| 4 | Jul 24, 2026 | 2026-07-24 16:05:18 | View |
Proxy statement (DEF 14A) disclosures
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure